Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Pathogenic Antibodies Decline Over Time in VITT

By LabMedica International staff writers
Posted on 25 Sep 2021
Vaccine-induced immune thrombotic thrombocytopenia (VITT) has been described after vaccination with the adenoviral vector vaccines. More...
A syndrome characterized by venous or arterial thrombosis, particularly at unusual sites including cerebral sinus venous thrombosis (CSVT)/splanchnic thrombosis, and mild to severe thrombocytopenia.

VITT is caused by platelet-activating anti–platelet factor 4 (PF4) IgG antibodies, the presence of which can be confirmed by anti–PF4–heparin IgG enzyme-linked immunosorbent assay (ELISA) in combination with PF4-enhanced washed-platelet–activation assays. Clinical and in vitro characteristics of acute VITT closely resemble (autoimmune) heparin-induced thrombocytopenia.

Medical Scientists at the Universitätsmedizin Greifswald (Greifswald, Germany) conducted a study involving 35 patients with serologically confirmed VITT (27 women and eight men; median age, 53 years [range, 18 to 77 years]). The patients’ clinical symptoms started between days five and 18 after vaccination. All the patients presented with thrombocytopenia, and 30 presented with thrombosis.

Anti-PF4 IgG antibodies were tested by PF4/heparin ELISA. The cut-off of the ELISA was defined as optical density (OD) 0.5; samples testing >0.5 - 1.0 were defined as positive, between >1.0 - 2.0 as strongly–positive; greater 2.0 OD were defined as very strongly positive. Platelet activation by the antibodies was tested in a PF4-dependent washed platelet assay. Negatively tested sera were repeated with a new panel of washed platelets on a different day. A positive result was defined as PF4-dependent activation of platelets (lag time, <30 min) of at least two of three different donors.

The scientists reported that results of the PF4-dependent platelet-activation assay became negative in 23 of 35 patients (66%). In 14 of the 15 patients (93%), with follow-up of more than 12 weeks the platelet-activation assay became negative within a median of 12 weeks. In addition, the median optical density on anti–PF4–heparin IgG ELISA declined by 53% between the first and last available blood samples (median optical density, 2.98 versus 1.39). However, full seroreversion to a negative ELISA result (i.e., an optical density of <0.5) was seen in only three patients. In one patient, PF4-dependent platelet-activating antibodies and ELISA optical density values of greater than 3.0 persisted for more than 12 weeks in association with recurrent episodes of thrombocytopenia.

The authors reported that to achieve full protection against coronavirus disease 2019 (Covid-19), a second vaccination is needed after a first dose of ChAdOx1 nCoV-19. On the basis of their small series of patients, subsequent vaccination with an mRNA vaccine appears to be safe after results of platelet-activation assays for VITT antibodies have become negative. When no platelet-activation assay is available, a substantial decline in the optical density on anti–PF4–heparin IgG ELISA may be used as a decision criterion. The study was published on September 8, 2021 in The New England Journal of Medicine.

Related Links:

Universitätsmedizin Greifswald


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
HPV Test
Allplex HPV28 Detection
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.